Background: Studies suggest that complementary and alternative medicine (CAM) is widely used in the European Union (EU). We systematically reviewed data, reporting research quality and the prevalence of CAM use by citizens in Europe; what it is used for, and why. Methods: We searched for general population surveys of CAM use by using Ovid MEDLINE (1948 (1989( to September 2010. Additional studies were identified through experts and grey literature. Cross-sectional, population-based or cohort studies reporting CAM use in any EU language were included. Data were extracted and reviewed by 2 authors using a pre-designed extraction protocol with quality assessment instrument. Results: 87 studies were included. Inter-rater reliability was good (kappa = 0.8). Study methodology and quality of reporting were poor. The prevalence of CAM use varied widely within and across EU countries (0.3-86%). Prevalence data demonstrated substantial heterogeneity unrelated to report quality; therefore, we were unable to pool data for meta-analysis; our report is narrative and based on descriptive statistics. Herbal medicine was most commonly reported. CAM users were mainly women. The most common reason for use was dissatisfaction with conventional care; CAM was widely used for musculoskeletal problems. Conclusion: CAM prevalence across the EU is problematic to estimate because studies are generally poor and heterogeneous. A consistent definition of CAM, a core set of CAMs with country-specific variations and a standardised reporting strategy to enhance the accuracy of data pooling would improve reporting quality.
Introduction
The use of complementary and alternative medicine (CAM) interventions such as acupuncture, homeopathy and herbal medicine has increased exponentially in western industrialised nations over the last 25 years [1] [2] [3] [4] . CAM is mainly used in addition to conventional care for many chronic and some January 1, 1989 to December 31, 2009 ) and 'human studies' but not language. Papers in EU languages were translated into English. The last search was run on September 29, 2010 . We also citation-searched all included studies, looked at reference lists of previously published reviews, requested further potentially relevant publications from CAM experts, CAM organisation and registration bodies and searched the electronic grey literature base OpenSIGLE.
We included population-based, cohort or cross-sectional studies of all ages of participants in any EU country and language, reporting the prevalence of use of CAM in general, or 1 or more specific CAMs broadly consistent with the National Center for Complementary and Alternative Medicine (NCCAM) definition [19] , and with assessment of at least 1 socio-demographic variable. We excluded non-peer reviewed, non-crosssectional or non-cohort studies, editorials, letters, theses and dissertations, case studies and congress abstracts. We further excluded unpublished or on-going studies, double publications and studies fo cussing exclusively on CAM use in disease-specific populations (e.g., cancer).
The full electronic search strategy for Ovid MEDLINE is reported in the on-line appendix 2 (available at http://content.karger.com/Produkte DB/produkte.asp?doi=342708).
Selection of Studies
One reviewer (Susan Eardley) checked the literature search, excluding articles that were not at all related to CAM. The titles, abstracts and (if necessary) full text copies of all remaining articles were then assessed independently for eligibility by 2 reviewers (Susan Eardley and Felicity Bishop). Disagreements were resolved by discussion; inter-rater agreement was calculated by Cohen's kappa. Full text copies of all eligible papers were obtained and translated into English as necessary.
Data Extraction and Quality Assessment Process
Using the pre-designed data extraction tool, 1 reviewer (Susan Eardley) extracted data from all 87 included papers on CAM prevalence, types of CAMs, demographic data, reasons for use and conditions treated. A second reviewer (Felicity Bishop) independently extracted data from a randomly selected sample of 20% of studies with good inter-rater agreement (kappa = 0.8). A third reviewer (George Lewith) extracted data on overall CAM prevalence from all included studies, and agreement was 96.5%. We assessed study quality using a pre-existing quality assessment tool (QAT) [8] based on the STROBE statement checklist for observational studies [20] comprising 16 items in 4 domains (appendix 3 available at http://content.karger.com/ProdukteDB/produkte.asp?doi=342708). The questions were weighted for importance for overall quality by the assignment of points (maximum score 16.5 points). Scores were transformed into percentage points. Disagreements were resolved by discussion.
Methods of Analysis
We used standard descriptive statistics and Forest plots to depict prevalence rates of overall CAM use and of the more widely recognised CAM modalities. We planned to perform Cochrane's test for heterogeneity before a meta-analysis to combine the information from the different studies
Results
All additional data are available in our complete CAMbrella Work Package 4 report, including tables, figures and protocols (www.cambrella.eu).
acute health conditions as well as for maintaining health. More than half of all breast cancer patients and up to 90% of people with chronic benign conditions, such as arthritis, use some CAM [5] . CAM is often used as a mechanism for minimising the use of conventional drugs and is frequently purchased over the counter (OTC) as a medicine in chronic disease. CAM is practised by both doctors and non-medically qualified individuals within the European Union (EU).
Recent reviews of CAM use in general populations across continents report prevalence rates of between 2.6 and 74.8% [6, 7] . Systematic reviews of CAM use in specific cancer populations suggest prevalence rates of between 11 and 91% [8] [9] [10] with rates in other conditions similarly wide ranging [11] [12] [13] . These reviews commonly report that the quality of included studies is highly variable, that there is a lack of a consistent operational definition of CAM, that the number and types of therapies included as CAM vary hugely from study to study and that prevalence is measured over differing time frames. Despite these short comings, reviews suggest that the prevalence of CAM use can be high.
Within Europe, surveys in the UK, Germany and Italy suggest that between 10 and 70% of the total population use CAM each year [2, 14, 15] . Despite data only being available from a few EU states, the global atlas of traditional and complementary medicine (World Health Organisation (WHO) Centre for Health Development) [16] suggests CAM is highly prevalent within the EU. Similarly, the European Information Centre for Complementary & Alternative Medicine (EICCAM) suggests that more than 100 million EU citizens are regular users of CAM, predominantly for chronic conditions [17] . There is an urgent need to identify accurate data on CAM prevalence across the EU so that we can develop an understanding of the medical and economic issues surrounding CAM use and its safe and legitimate provision to EU citizens. We therefore aimed to: -address the prevalence of CAM use in Europe from (normally cross-sectional) population-based studies, -determine which CAMs are used and for which conditions, -explore the reasons why patients choose CAM, -assess the quality of the data available and quality of reporting.
Methods
The details of the review methodology and data extraction tool were developed by the CAMbrella management group (appendix 1 available at http://content.karger.com/ProdukteDB/produkte.asp?doi=342708). We followed the PRISMA statement guidelines for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions [18] .
Literature Search
Using the NCCAM definition of CAM [19] ). Studies scoring <50% were empirically defined as low quality and studies scoring >60% were considered to have higher quality [8] . Table 1 reports the number of studies in each percentage range. Figure 1 reports the flow of information through the study. After excluding clearly ineligible studies, 187 studies were assessed in detail for eligibility ( fig. 1 ). Inter-rater reliability for inclusion was good (Cohen's kappa = 0.70 [21] ). No eligible studies were found in the grey literature. 87 studies that reported the prevalence of CAM use were included in the final analysis. Sample sizes varied from small studies of 92 participants [22] to population surveys of 57,717,200 [15] (median 1,785). We did not locate any general population data on CAM use for 22 (64%) EU member states and associated countries based on our study inclusion criteria (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Estonia, Romania, Latvia, Lithuania, Luxembourg, Malta, Slovakia, Greece, Hungary, Use of herbal medicine was reported in 31 papers [2, 15, 22, 26, 33, 48, 52, 53, 55-63, 65, 66, 68, 70-73, 75, 86, 88, 93, 94, 101, 102] . Prevalence rates varied from 5.9 to 48.3%, numbers of users 1-27,704,256, sample sizes 341-57,717,200; however, its use was not well defined (it may be included in naturopathy, folk medicine or Traditional Chinese Medicine) and variously categorised as medical herbalism, herbal remedies, herbal teas or phytotherapy. Some specific herbs were reported by name, e.g., St. Johns Wort. Homoeopathy was reported separately in 25 studies. Prevalence rates varied from 2 to 27%, numbers of users 3-4,732,810 and sample sizes 341-57,717,200. We were unable to calculate the overall prevalence rate for herbal medicine or homoeopathy, either by country or across the EU, as they were reported as 1 possible method in a group of CAM therapies patients might have used in 10 of the studies. IndiThe main methodological weaknesses identified were: CAM was not defined to survey participants in 32% of papers . Only 29% reported pilot studies of the questionnaire used [22, 24, 27, 28, 41, 43, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] and 79% reported data collection strategies that were subject to recall bias (recall over 12 months or more ) [ 
Study Selection and Characteristics

Prevalence of CAM Use
While there was a small number of rigorous prevalence studies based on nationally representative samples [1, 86] , the vast majority of studies were small and of poor quality. Figure 2 presents a Forest plot of CAM use in the EU states for which we had information. The data were very heterogeneous. Therefore, Cochran's test for heterogeneity, which we had planned to perform, was determined to be both unnecessary and irrelevant. We were, therefore, unable to pool the data in a meta-analysis. The included studies did not report data consistently, thus the results are presented as a narrative. The prevalence of CAM use, reasons for use and conditions treated may be found in appendix 5 (available at http://content.karger.com/ProdukteDB/produkte.asp?doi=342708).
Since data had been collected over a wide variety of time periods ('last 24 hours' to 'ever used'), using different definitions of CAM, the use of 'any CAM at any time' was the only reasonable method of summarising prevalence of use. Overall use across countries was reported between 0.3 and 86% (median 29%, mean 30%, mode 10%). Table 2 reports prevalence of use by country.
Types of CAM Reported
The results of the top 5 most commonly reported therapies from countries for which we had data are reported in table 3. [28] . Prevalence rates varied from 0.4 to 21%, user numbers 10-3,505 in sample sizes of 341-15,465. We were unable to calculate the overall prevalence rate for chiropractic, acupuncture or reflexology by either country or across the EU. Considering dietary supplements, calcium supplement use was reported in 9 studies [2, 22, 38, 45, 64, 72, 92, 103, 104] . Use of all other dietary supplements, vitamins, minerals, fish oils, glucosamine and other products was reported heterogeneously in groups, singly or combinations of supplements in 28 papers [22, 23, 35, 37-39, 45, 47, 49, 56, 57, vidual therapy prevalence rates for herbal medicine and homeopathy cannot be ascertained from these specific datasets. It could have varied from 'no use at all' to 'all participants using' in these papers. We were unable to differentiate between practitioner-or doctor-based prescriptions and OTC purchases.
Chiropractic was reported in 17 studies [2, 30, 32, 34, 55, 58-60, 62, 66-68, 74, 82, 85, 86, 94] , as 'chiropractic or osteopathy' in 1 study [41] , as 1 of a group of CAMs in 4 studies [28, 31, 53, 77] , and as 'manual or manipulative treatments' in 2 studies [15, 61] . Prevalence rates were 0.4-20.8%, user numbers 5-4,040,204 and sample sizes of 152-57,717,200. Acupuncture was reported in 14 studies [2, 15, 24, 30, 34, 56, 58-60, 62, 66, 68, 80, 86] but was poorly defined. Prevalence rates were 0.44-23%, numbers of users 4-1,673,799, sample Further data about other therapies are available in our full report (www.cambrella.eu).
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Who Uses CAM, Why and What for?
Musculoskeletal problems were reported as the condition most commonly treated with CAM (appendix 6 available at descriptive, weak data, and lack any information at all for a number of EU countries. Reported prevalence rates of CAM use were 0.3-86% but, due to heterogeneity, we were unable to pool the data in a meta-analysis. Herbal medicine was the most frequently reported CAM. Musculoskeletal problems were the most reported condition and disappointment with
Discussion
Summary
While there are a few rigorous prevalence studies that are based on nationally representative samples, the vast majority is small and of poor quality. Consequently, we can only report 
Strengths and Limitations
The strengths of this study were the rigorous methodology, extensive searching and the detailed data extraction tool. Our quality scoring instrument also provided a detailed and comprehensive set of basic data and socio-demographic characteristics. Inter-rater agreements were good for data extraction. Although our literature search was thorough, we could not locate studies from all the EU member states. Some studies we did locate were unavailable to us; therefore, it is possible that along with our inclusion and exclusion criteria, we missed some potentially relevant information. Our quality scoring instrument is potentially open to error because we are not certain which study characteristics may be associated with CAM use.
Comparisons with Other Studies
As in other studies, we were unable to draw firm conclusions about CAM use across the EU due to the heterogeneity of the studies we included and a lack of data from more than half of the EU member and associated states [16] . Our data concur with other studies indicating than CAM use may be highly prevalent [7] , that women use CAM more than men [108] , that musculoskeletal problems are the main conditions for which CAM is sought [19] and that dissatisfaction with orthodox treatment is a common reason for CAM use [109] .
Improvements for Future Studies
Future studies of CAM prevalence should consider including: a set of core definitions (variable by country), standardised survey methodology according to good epidemiological practice [20] , efforts to manage recall bias and utilise representative samples, definitions of CAM as practitioner provided or OTC purchase, collection of data on medical conditions for which CAM is used and reasons for use and a standardised set of socio-demographic variables to help enable data pooling and the accuracy of reports. It would also be important to understand how CAM use in the general population differs from ill population, as we are aware that CAM is used mainly in addition to conventional care, but that its use is not often disclosed. This is potentially problematic due to interactions with conventional medications [110] , and comparison studies between these different populations would be pertinent. Future studies would ideally investigate reports from across the EU and particularly involved states for which we have no data. We suggest that Thomas et al. [68] offer a good model for conducting this type of research. It enquires about the CAMs commonly used in the target population, has a clear power calculation and a reliable response rate and reports data in a conservative and thoughtful manner.
Conclusions
There are limited conclusions about CAM use that may be drawn from this review, primarily due to the heterogeneity and poor quality of the studies we included. We considered western medicine a main reason for CAM use, although it is not possible to derive definitive conclusions due to the small numbers of studies reporting these data.
Data Extraction
Our extraction protocol had been developed for a comprehensive and detailed report of CAM use, but the included studies reported so heterogeneously that we had large areas of missing data. Some of our categories were not reported in any study, e.g., medical or non-medical CAM provider; therefore, we cannot make any firm statements about the proportions of different types of provider. We have limited information on the economic issues surrounding CAM use. No study reported whether CAM was paid for by health insurance companies and only 1 study reported data pertaining to the out of pocket expenses for CAM.
We identified several limitations, e.g., wide-ranging definitions of CAM contributed to the variation in prevalence rates; therefore, the use of core definitions for the main CAM disciplines, variable by country, could improve the accuracy with which CAM use is measured. The accuracy of measuring instruments that were not piloted and validated is unclear as they are potentially subject to recall and other bias. A lack of standardisation in the collection of socio-demographic data hampered our ability to evaluate this information across the study population.
Prevalence of CAM Use
Prevalence rates in specific countries were wide and we were unable to determine whether their use was OTC purchase or practitioner delivered. Mansky et al. [5] reported the use of CAM by up to 90% of patients for some benign conditions, corresponding to those higher prevalence rates reported in this review, with the lower prevalence rates reported here being similar to previous surveys in the UK and Germany [2, 14] . Frass et al. [6] report a similarly wide range of prevalence rates, although data were included from non-EU countries. CAM use was measured as specific therapies, as groups of therapies or as umbrella terms such as 'complementary medicine' where no therapy was specified; therefore, we were unable to draw any meaningful conclusions about the prevalence of individual CAMs. We were able to ascertain the most commonly reported CAMs in countries for which we had data, although this is limited due to a lack of clear definitions of individual CAMs. Only 10% of studies reported the conditions for use: musculoskeletal problems were reported most commonly, reflecting the recent figures from the NCCAM [19] . Similarly, studies of acupuncture and chiropractic report musculoskeletal problems as the main condition treated [107] . While most of the included papers reported some demographic information, few reported this in sufficient detail for us to make any firm conclusions about the sections of the population who uses CAM. Previous studies report that more women than men use CAM [19] , which was also suggested in our data.
Eardley/Bishop/Prescott/Cardini/Brinkhaus/ Santos-Rey/Vas/von Ammon/Hegyi/Dragan/ Uehleke/Fønnebø/Lewith pies as well as the large evidence gaps. Further high quality and standardised prevalence research is essential to enable us to build a picture of current use and future needs. sub-group analyses by country and by type of CAM but did not find convincing evidence for these data being any more homogenous and suitable for pooling in a meta-analysis. We had data from less than half the EU member states with several countries only being represented by 1 or 2 papers so the overall picture of CAM use was unclear.
Disclosure Statement
The need for a valid questionnaire on CAM use, standardised (but variable for different countries) would increase the accuracy of data collection and enable data pooling. Such a questionnaire has recently been piloted by the CAMbrella team for use across the EU member states [111] .
In conclusion, we were unable to report the prevalence of CAM across the EU member and associated states due to the heterogeneity and poor quality of the included studies. We were able to identify the current most commonly used thera-
